GlassScriptPhysician profile
Cathy Clubb
NPI 1780639807
$1,738.75
in general payments reported to CMS, 2019-2025
26 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $188 · 2021: $362 · 2022: $349 · 2023: $334 · 2024: $89.83 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.77 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $265.23 | 2020-2025 | Veozah, Myrbetriq |
| Myovant Sciences INC. | $162.26 | 2021-2022 | |
| Medtronic, INC. | $159.65 | 2025 | Truclear |
| Gynesonics, INC. | $90.51 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $88.25 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $87.43 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $45.42 | 2023 | Myfembree |
| Pfizer INC. | $36.73 | 2021-2022 | |
| Sage Therapeutics, LLC | $36.28 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $30.52 | 2019-2022 | |
| Avion Pharmaceuticals | $29.42 | 2019 | |
| Agile Therapeutics, INC. | $28.99 | 2021-2023 | Twirla |
| Exeltis, USA INC. | $25.62 | 2019-2024 | Slynd |
| Kowa Pharmaceuticals America, INC. | $22.67 | 2023 | Seglentis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $22.21 | 2019 | |
| Exact Sciences Corporation | $21.42 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $20.23 | 2024 | Injectafer |
| Coopersurgical, INC. | $17.86 | 2020 | |
| Ascend Therapeutics US, LLC | $17.00 | 2023 | |
| Organon LLC | $15.45 | 2024 | |
| Allergan, INC. | $15.41 | 2019 | |
| Therapeuticsmd, INC. | $13.73 | 2020 | |
| Minerva Surgical, INC | $12.65 | 2020 | |
| Aspira Women'S Health INC | $12.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Clubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.